Trial Profile
A study to evaluate biochemical response to enzalutamide therapy in patients with metastatic castrate resistant prostate cancer
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 13 Dec 2015
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary) ; Abiraterone; Docetaxel
- Indications Prostate cancer
- Focus Expanded access; Therapeutic Use
- Sponsors Astellas Pharma
- 13 Dec 2015 New trial record